Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy…
| Price | $106.17 |
|---|---|
| Market cap | $4.44B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NYSE |
| 52-week range | 32-131.24 |
| Beta | 1.23 |
Explore MANE's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.